- Home
- DMA vs CRVO Comparison
DMA vs CRVO Comparison
Compare DMA & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | CRVO |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 78.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DMA | CRVO |
|---|---|---|
| Price | $8.98 | $7.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 34.6K | ★ 55.4K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.78 | $1.92 |
| 52 Week High | $8.00 | $16.94 |
Technical Indicators
Market Signals| Indicator | DMA | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 45.09 |
| Support Level | $8.97 | $7.60 |
| Resistance Level | $9.15 | $8.46 |
| Average True Range (ATR) | 0.14 | 0.53 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 26.09 | 38.78 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.